BL
BioLife Solutions, Inc.
BLFS · NASDAQ
$36.69 -0.11% (-$0.04)
1M -1.34%
Market Cap $1.79B
P/E Ratio 35.53x
Div. Yield -
ROE 13.29%
Bulios Fair Price
$32.38
11.7% downside
Current Price
$36.69
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BLFS is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
12 /100
Expensive P/S 17.43x
P/E 35.53x
P/B 4.27x
Growth
52 /100
Stable Book val. growth 0.70%
Rev. growth 8.07%
FCF growth N/A
Profitability
49 /100
Moderate Op. margin 7.25%
Gross margin 64.48%
FCF margin 0.88%
Quality
59 /100
Average ROA 11.27%
ROIC 10.69%
Asset turnover 0.23x
Debt
97 /100
Low Int. coverage 9.40x
Debt/Equity 0.04x
Net debt/EBITDA -0.84x
Stability
60 /100
Moderate EPS volatility 14.07%
Beta 1.92x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BLFS
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Roderick de Greef
Employees
155
Headquarters
Bothell
Upcoming events
05 NOV
Earnings
Upcoming earnings report